Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy
- 1 March 2003
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (4) , 438-446
- https://doi.org/10.1016/s0959-8049(02)00732-3
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1998
- erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell LymphomaNew England Journal of Medicine, 1997
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- Primary Systemic Treatment with Weekly Doxorubicin Monotherapy in Women with Locally Advanced Breast Cancer; Clinical Experience and Parameters Predicting OutcomeActa Oncologica, 1996
- Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases.Journal of Clinical Oncology, 1995
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignanciesBlood, 1994
- p53-dependent apoptosis modulates the cytotoxicity of anticancer agentsCell, 1993
- Growth Rate Patterns of Solid Tumors and Their Relation to Responsiveness to TherapyAnnals of Internal Medicine, 1978